Adaptive Biotechnologies‘ stock rose 6 percent to $30 per share in after-hours trading on Tuesday after the company reported higher revenues and narrower losses than expected for its third-quarter earnings.… Read More
Adaptive Biotechnologies has signed a $300 million collaborative licensing agreement with Genentech to develop highly personalized cancer therapies. In addition to the up-front payment, Adaptive could receive up to $2… Read More